Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose
- 510 Downloads
Nevirapine (NVP) extensive data obtained after oral single dose administration of 200 mg in a crossover study involving 16 healthy subjects was used to develop a descriptive population pharmacokinetic model including drug recirculation, since secondary peaks were observed in plasma concentration-time profiles for all subjects. Through implementation of model event time feature in NONMEM 7.3.0, a simple mechanistic model physiologically consistent with the process of drug cycling was able to describe multiple peaks phenomena and quantify its pharmacokinetic parameters, achieving a better performance than its analogue conventional one. Absorption process, between subject and-between occasion variability of pharmacokinetic parameters was also assessed. Estimated mean fraction of NVP bioavailable dose undergoing recirculation process was 51.6 %, a magnitude which could hardly be explained by enterohepatic cycling. In this work we propose an alternative disposition process to explain NVP drug recirculation: gastric secretion with posterior intestinal reabsorption. Due to physicochemical and pharmacokinetic properties of the drug, this neglected phenomenon is more likely to explain the results obtained, and might be present in disposition of several basic drugs.
KeywordsDrug recirculation Nevirapine Population pharmacokinetic modelling
We acknowledge the scientific support given by Uppsala Pharmacometric Summer School event held on August 5–16, 2013.
Conflict of interest
Authors have no conflict of interest to declare.
- 1.World Health Organization (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress ReportGoogle Scholar
- 2.World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approachGoogle Scholar
- 3.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 1 Jan 2014
- 4.Hawi A, Bell G (1994) Preformulation studies of nevirapine, a reverse transcriptase inhibitor. Pharm Res 11:236Google Scholar
- 5.VIRAMUNE® prescribing information (2012) Boehringer Ingelheim Pharmaceuticals IncGoogle Scholar
- 9.Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, Piscitelli SC (2005) Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 41:1789–1793Google Scholar
- 10.van Praag RM, van Weert EC, van Heeswijk RP, Zhou XJ, Sommadossi JP, Jurriaans S, Lange JM, Hoetelmans RM, Prins JM (2002) Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy. Antimicrob Agents Chemother 46(3):889–896Google Scholar
- 13.Janneh O, Chandler B, Hartkoorn R, Kwan WS, Jenkinson C, Evans S, Back DJ, Owen A, Khoo SH (2009) Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 64:1002–1007PubMedCrossRefGoogle Scholar
- 18.Havlir D, Cheesman SH, Mclaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M, Richman DD (1995) High-dose nevirapine: safety, pharmacokinetics, and antiretroviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171(3):537–545PubMedCrossRefGoogle Scholar
- 19.Zhou XJ, Sheiner LB, D’Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M, Sommadossi JP (1999) Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 43(1):121–128PubMedCentralPubMedGoogle Scholar
- 21.Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM (2010) Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 54:4432–4439PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fatkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ (2011) Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 66:1332–1339PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Svensson E, van der Walt JF, Barnes KI, Cohen K, Kredo T, Huitema A, Nachega JB, Karlsson MO, Denti P (2012) Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol 74(3):465–476PubMedCentralPubMedCrossRefGoogle Scholar
- 25.Hamrapurkar P, Phale M, Patil P, Shah N (2010) Determination of nevirapine in plasma by high performance liquid chromatography with ultraviolet detection. Int J Pharm Tech Res 2(2):1316–1324Google Scholar
- 26.Beal S, Sheiner LB, Boeckmann A, Bauer RJ (1989–2011) NONMEM user’s guides. Ellicott City,MD, USA: Icon Development SolutionsGoogle Scholar
- 32.Boeckmann A, Sheiner LB, Beal SL (2011) NONMEM user’s guide part V. Ellicott City,MD, USA: Icon Development SolutionsGoogle Scholar
- 38.Hall JE (2010) Guyton and Hall textbook of medical physiology, 12th edn. Saunders, PhiladelphiaGoogle Scholar